A detailed history of Tower Research Capital LLC (Trc) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,301 shares of IONS stock, worth $149,459. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,301
Previous 49,986 91.4%
Holding current value
$149,459
Previous $2.38 Million 92.78%
% of portfolio
0.0%
Previous 0.04%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.06 - $51.86 $1.83 Million - $2.37 Million
-45,685 Reduced 91.4%
4,301 $172,000
Q2 2024

Aug 13, 2024

BUY
$36.45 - $47.7 $1.64 Million - $2.15 Million
45,123 Added 927.88%
49,986 $2.38 Million
Q1 2024

May 15, 2024

BUY
$42.03 - $53.55 $63,171 - $80,485
1,503 Added 44.73%
4,863 $210,000
Q4 2023

Feb 13, 2024

BUY
$43.39 - $51.63 $106,912 - $127,216
2,464 Added 275.0%
3,360 $169,000
Q3 2023

Nov 14, 2023

SELL
$38.5 - $47.13 $192,192 - $235,272
-4,992 Reduced 84.78%
896 $40,000
Q2 2023

Aug 14, 2023

SELL
$34.73 - $43.33 $320,592 - $399,979
-9,231 Reduced 61.06%
5,888 $241,000
Q1 2023

May 09, 2023

BUY
$33.58 - $41.2 $263,502 - $323,296
7,847 Added 107.91%
15,119 $540,000
Q4 2022

Feb 10, 2023

SELL
$37.12 - $46.52 $166,408 - $208,549
-4,483 Reduced 38.14%
7,272 $275,000
Q3 2022

Nov 10, 2022

BUY
$36.54 - $48.66 $377,275 - $502,414
10,325 Added 722.03%
11,755 $520,000
Q2 2022

Aug 15, 2022

SELL
$31.71 - $43.0 $231,419 - $313,814
-7,298 Reduced 83.62%
1,430 $53,000
Q1 2022

May 12, 2022

BUY
$29.88 - $37.04 $224,159 - $277,874
7,502 Added 611.91%
8,728 $323,000
Q4 2021

Feb 14, 2022

BUY
$25.61 - $35.1 $11,037 - $15,128
431 Added 54.21%
1,226 $37,000
Q3 2021

Nov 15, 2021

SELL
$33.54 - $40.55 $314,873 - $380,683
-9,388 Reduced 92.19%
795 $27,000
Q2 2021

Aug 16, 2021

SELL
$34.54 - $47.25 $73,915 - $101,115
-2,140 Reduced 17.37%
10,183 $406,000
Q1 2021

May 17, 2021

SELL
$42.51 - $63.78 $196,396 - $294,663
-4,620 Reduced 27.27%
12,323 $554,000
Q4 2020

Feb 16, 2021

SELL
$45.3 - $60.27 $38,595 - $51,350
-852 Reduced 4.79%
16,943 $958,000
Q3 2020

Nov 16, 2020

BUY
$47.45 - $62.95 $818,417 - $1.09 Million
17,248 Added 3153.2%
17,795 $844,000
Q2 2020

Aug 13, 2020

SELL
$46.85 - $61.05 $324,904 - $423,381
-6,935 Reduced 92.69%
547 $33,000
Q1 2020

May 15, 2020

BUY
$41.6 - $63.4 $311,251 - $474,358
7,482 New
7,482 $354,000
Q4 2019

Feb 07, 2020

SELL
$53.85 - $65.27 $4,469 - $5,417
-83 Closed
0 $0
Q3 2019

Nov 05, 2019

SELL
$59.06 - $72.15 $104,477 - $127,633
-1,769 Reduced 95.52%
83 $5,000
Q2 2019

Aug 13, 2019

BUY
$62.09 - $86.14 $114,990 - $159,531
1,852 New
1,852 $119,000
Q1 2019

May 14, 2019

SELL
$52.92 - $81.17 $2,010 - $3,084
-38 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$43.37 - $59.54 $76,634 - $105,207
-1,767 Reduced 97.89%
38 $2,000
Q3 2018

Nov 13, 2018

BUY
$42.88 - $53.7 $46,096 - $57,727
1,075 Added 147.26%
1,805 $93,000
Q2 2018

Aug 15, 2018

SELL
$40.53 - $50.7 $388,723 - $486,263
-9,591 Reduced 92.93%
730 $30,000
Q1 2018

May 15, 2018

BUY
$44.08 - $55.05 $454,949 - $568,171
10,321 New
10,321 $455,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $4.93B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.